Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Multi-Center, Dose Escalation/Dose Expansion, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors

NCT03565003 is registered in ClinicalTrials.gov with Jacobio Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT03565003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03565003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Multi-Center, Dose Escalation/Dose Expansion, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
November 20, 2018
Completion date
January 31, 2023
Enrollment
126 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, head and neck cancer, non-small cell lung cancer, other metastatic solid tumors